To assess the safety and effectiveness of the Juvene® IOL for the treatment of aphakia and mitigation of the effects of presbyopia after removal of the natural crystalline lens due to cataract.

Key Inclusion Criteria:

• Subjects must be 22 years of age or older
• Able to comprehend and provide written informed consent
• Willing and able to comply with schedule for follow-up visits
• Demonstrate sufficient cognitive awareness to comply with examination procedures
• Other inclusion criteria specified in the protocol may apply.

Key Exclusion Criteria:

• Subjects with clinically significant dry eye syndrome (DES) expected to impact postoperative visual acuity
• Subjects taking medications that may affect ocular function (including but not limited to mydriatic, cycloplegic and miotic agents; tricyclic antidepressants, phenothiazines, benzodiazepines, first generation antihistamines, and anticholinergic agents)
• Prior intraocular or corneal surgery (including corneal refractive correction i.e., LASIK, PRK, etc.)
• Any corneal dystrophy that may affect visual acuity (e.g., keratoconus, pellucid corneal degeneration, etc.)
• Other exclusion criteria specified in the protocol may apply.

The subject will be masked to randomization assignment and will be unmasked at the completion of the study. Scheduled masked postoperative assessments will be performed by a masked examiner